2. Signaling Pathways
  3. Epigenetics
  4. Histone Acetyltransferase

Histone Acetyltransferase

Acetyltransferase

HATs; HAT

Histone Acetyltransferase

Related Products

PDF 0.82 MB

Histone acetyltransferases (HATs) are epigenetic enzymes that install acetyl groups onto lysine residues of cellular proteins such as histones, transcription factors, nuclear receptors, and enzymes. HATs are crucial for chromatin restructuring and transcriptional regulation in eukaryotic cells. HATs have been shown to play a role in diseases ranging from cancer and inflammatory diseases to neurological disorders, both through acetylations of histone proteins and non-histone proteins.

HATs can be grouped into at least five different subfamilies (HAT1, Gcn5/PCAF, MYST, p300/CBP, and Rtt109). HATs mediate many different biological processes including cell-cycle progression, dosage compensation, repair of DNA damage, and hormone signaling. Aberrant HAT function is correlated with several human diseases including solid tumors, leukemias, inflammatory lung disease, viral infection, diabetes, fungal infection, and drug addiction.

Histone Acetyltransferase Isoform Specific Products:

Histone Acetyltransferase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P2515
    Transcriptional Intermediary Factor 2 (TIF2) (740-753)
    		Agonist
    Transcriptional Intermediary Factor 2 (TIF2) (740-753) is a TIF-2 coactivator peptide composed of 14 amino acids and covers the residue range 740-753 of TIF-2 protein.
    Transcriptional Intermediary Factor 2 (TIF2) (740-753)
  • HY-139861
    CBP/p300-IN-14
    		Inhibitor
    CBP/p300-IN-14 is a potent inhibitor of CBP/EP300 (lysine acetyltransferase) with an IC50 of 3.3 nM (extracted from patent WO2021213521A1, compound 27).
    CBP/p300-IN-14
  • HY-143442
    CBP/p300-IN-18
    		Inhibitor
    CBP/p300-IN-18 (compound 8) is a potent EP300/CBP HAT inhibitor with IC50s of 0.056, 0.46 µM for HAT EP300 and LK2 H3K27, respectively.
    CBP/p300-IN-18
  • HY-128367
    Ep300/CREBBP-IN-4
    		Inhibitor
    Ep300/CREBBP-IN-4 (Example 56) is a potent Ep300 and CREBBP inhibitor with IC50s of 0.024 and 0.064 μM, respectively. Ep300/CREBBP-IN-4 can be used for the research of cancer.
    Ep300/CREBBP-IN-4
  • HY-155229
    CBP/p300-IN-21
    		Inhibitor
    CBP/p300-IN-21 (Compound 5d) is a selective CBP/p300 inhibitor (IC50: 0.07 and 1.755 μM for p300 and CBP). CBP/p300-IN-21 decreases H3K18Ac level. CBP/p300-IN-21 inhibits growth of 4T1 tumor growth in mice.
    CBP/p300-IN-21
  • HY-143339
    CBP/p300-IN-15
    		Inhibitor
    CBP/p300-IN-15 (compound 13a) is a potent p300/CBP inhibitor, with IC50 values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC50 values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research.
    CBP/p300-IN-15
  • HY-128364
    Ep300/CREBBP-IN-3
    		Inhibitor
    Ep300/CREBBP-IN-3 (Example 61) is a potent Ep300 and CREBBP inhibitor with IC50s of 0.056 and 0.095 μM, respectively. Ep300/CREBBP-IN-3 can be used for the research of cancer.
    Ep300/CREBBP-IN-3
  • HY-146445
    P300 bromodomain-IN-1
    		Inhibitor
    P300 bromodomain-IN-1 (Compoun 1u) is a potent p300 (EP300) bromodomain inhibitor with an IC50 of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and apoptosis in OPM-2 cells.
    P300 bromodomain-IN-1
  • HY-143440
    CBP/p300-IN-16
    		Inhibitor
    CBP/p300-IN-16 (compound 1) is a potent EP300/CBP HAT inhibitor with IC50s of 0.61, 2.24 µM for HAT EP300 and LK2 H3K27, respectively.
    CBP/p300-IN-16
  • HY-121089
    P300-IN-5
    		Inhibitor
    P300-IN-5 is a biological inhibitor that demonstrates potent activity against histone acetyltransferases (HAT) both in vitro and in vivo. P300-IN-5 may serve as an alternative therapeutic agent, especially in contexts requiring caution, such as during breastfeeding.
    P300-IN-5
  • HY-164005
    CBP/EP300 bromodomain receptor-IN-1
    		Inhibitor
    CBP/EP300 bromodomain receptor-IN-1 (Compound 10) is an inhibitor for CBP/EP300 bromodomain receptor, which binds to proteins having a bromodomain in nanomolar level.
    CBP/EP300 bromodomain receptor-IN-1
  • HY-N2345R
    Procyanidin B3 (Standard)
    		Inhibitor
    Procyanidin B3 (Standard) is the analytical standard of Procyanidin B3. This product is intended for research and analytical applications. Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis.
    Procyanidin B3 (Standard)
  • HY-147261
    B026
    		Inhibitor
    B026 is a selective, potent, orally active p300/CBP histone acetyltransferase (HAT) inhibitor with IC50 values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines.
    B026
  • HY-11055
    KP 544
    KP 544 is a potent neurotrophic protein enhancer that amplifies nerve growth factor (NGF)-induced neurite outgrowth of PC12 cells and SH-SY5Y neuroblastoma cells. KP544 also enhances choline acetyltransferase activity. KP 544 selectively interact in the differentiation pathway downstream of MAPK in a manner that amplifies nerve growth factor and cyclic AMP effects and is also neuroprotective.
    KP 544
  • HY-162128
    Antitumor agent-130
    		Inhibitor
    Antitumor agent-130 (Compound 7b) is a p300 histone acetyltransferases (HAT) inhibitor with an IC50 of 1.51 μM. Antitumor agent-130 combinates with doxorubicin (HY-15142A) can significantly inhibit tumor growth and invasion in vitro and in vivo.
    Antitumor agent-130
  • HY-162994
    KAT6A-IN-1
    		Inhibitor
    KAT6A-IN-1 (compund 5) is a KAT6A inhibitor.
    KAT6A-IN-1
  • HY-RS07083
    KAT7 Human Pre-designed siRNA Set A
    		Inhibitor

    KAT7 Human Pre-designed siRNA Set A contains three designed siRNAs for KAT7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    KAT7 Human Pre-designed siRNA Set A
    KAT7 Human Pre-designed siRNA Set A
  • HY-128363
    Ep300/CREBBP-IN-2
    		Inhibitor
    Ep300/CREBBP-IN-2 (Example 73) is a potent and orally active Ep300 and CREBBP inhibitor with IC50s of 0.052 and 0.148 μM, respectively. Ep300/CREBBP-IN-2 can be used for the research of cancer.
    Ep300/CREBBP-IN-2
  • HY-143441
    CBP/p300-IN-17
    		Inhibitor
    CBP/p300-IN-17 (compound 7) is a potent EP300/CBP HAT inhibitor with IC50s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively.
    CBP/p300-IN-17
  • HY-147289
    NSC 698600
    		Inhibitor
    NSC 698600 is a potent PCAF inhibitor, with IC50 of 6.51 µM (PCAF/H31-21). NSC 698600 exhibits good activity of inhibiting the proliferation of cancer cells.
    NSC 698600
Cat. No. Product Name / Synonyms Application Reactivity
Histone Acetyltransferase Isoform Comparison

CBP/p300

GCN5/PCAF

TIP60

MOZ/MORF

HBO1

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Histone Acetyltransferase Inhibitors & Activators
Product NameCBP/p300GCN5/PCAFTIP60MOZ/MORFHBO1Purity    
Curcumin
CBP/p300
    98.84%
A-485
CBP/p300
    99.87%
C646
CBP/p300
    99.88%
SGC-CBP30
CBP/p300
    99.83%
WM-3835    
HBO1
99.78%
PF-9363   
MOZ/MORF
 99.64%
Butyrolactone 3 
GCN5, IC50: 100 μM
   99.58%
CTB
CBP/p300
    99.93%
Anacardic Acid
p300-HAT, IC50: 8.5 μM
PCAF, IC50: 5 μM
   98.86%
MG 149
CBP/p300
 
TIP60
  99.24%
NSC 228155
KIX-KID, IC50: 0.36 μM
    ≥98.0%
WM-1119   
MOZ/MORF
 99.57%
WM-8014   
MOZ/MORF
 99.81%
PU139
CREBBP, IC50: 2.49 μM
p300, IC50: 5.35 μM
GCN5, IC50: 8.39 μM
PCAF, IC50: 9.74 μM
   99.14%
Garcinol 
GCN5/PCAF
   ≥99.0%
CPI-1612
CBP/p300
    99.74%
NEO2734
CBP/p300
    99.63%
CPTH2 
GCN5
   99.82%
TTK21
CBP/p300
    99.39%
GSK 4027 
GCN5/PCAF
   98.01%
TH1834  
TIP60
  99.60%
CTPB
CBP/p300
    ≥99.0%
YF-2
CBP, EC50: 2.75 μM
GCN5, EC50: 49.31 μM
GCN5/PCAF, EC50: 29.04 μM
   98.76%
GNE-272
CBP/p300
    99.60%
I-CBP112
CBP/p300
    98.20%
PF-CBP1 hydrochloride
CREBBP, IC50: 125 nM
EP300, IC50: 363 nM
CBP, Kd: .19 μM
    99.96%
GNE-207
CBP, IC50: 1 nM
    99.94%
TH1834 dihydrochloride  
TIP60
  99.68%
L002
CBP/p300
    99.44%
Histone Acetyltransferase Inhibitor II
CBP/p300
    99.01%
CBP/p300-IN-3
CBP/p300
    98.95%
Procyanidin B3
CBP/p300
    99.92%
YF-2 hydrochloride
CBP, EC50: 2.75 μM
GCN5, EC50: 49.31 μM
GCN5/PCAF, EC50: 29.04 μM
   99.61%
CBP/p300-IN-12
CBP/p300, IC50: 166 nM
    99.72%
PCAF-IN-2 
PCAF, IC50: 5.31 μM
   ≥98.0%
GSK4028 
GCN5/PCAF
   98.06%
TPOP146
CBP/p300
    98.98%
Lys-CoA TFA
p300, IC50: 50-500 nM
    99.42%
CBP/p300-IN-10
EP300, IC50: 26 nM
CREBBP, IC50: 39 nM
    98.69%
Curcumin-d6
CBP/p300
    99.78%
NSC 694623 
PCAF, IC50: 15.9 μM
   99.36%
CBP/p300-IN-19 hydrochloride
p300-HAT, IC50: 1.4 μM
CBP-HAT, IC50: 2.2 μM
PCAF, IC50: >100 μM
   
MOZ-IN-2   
MOZ/MORF
 99.87%
NiCur
CBP-HAT, IC50: 0.35 μM
    99.11%
CBP/p300-IN-20
CBP/p300, pIC50: 10.1
    98.03%
DCH36_06
CBP/p300
    99.19%
Naphthol AS-E
KIX-KID, IC50: 2.26 μM
    ≥98.0%
CBP/p300-IN-5
CBP/p300
    
CPTH2 hydrochloride 
GCN5
   
DS17701585
EP300, IC50: 0.04 μM
CBP, IC50: 0.15 μM
    
CBP/p300-IN-14
CBP/p300
    
CBP/p300-IN-18
EP300, IC50: .056 μM
    
Ep300/CREBBP-IN-4
EP300, IC50: 0.024 μM
CREBBP, IC50: 0.064 μM
    
CBP/p300-IN-15
CBP, IC50: 28 nM
p300, IC50: 2.5 nM
    
Ep300/CREBBP-IN-3
EP300, IC50: 0.056 μM
CREBBP, IC50: 0.095 μM
    
P300 bromodomain-IN-1
p300, IC50: 49 nM
    
B026
p300, IC50: 8.1 nM
CBP, IC50: 9.5 nM
    
Ep300/CREBBP-IN-2
EP300, IC50: 0.052 μM
CREBBP, IC50: 0.148 μM
    
CBP/p300-IN-17
EP300, IC50: .18 μM
    
CAY10669 
PCAF, IC50: 662 μM
   
Ep300/CREBBP-IN-8
EP300, IC50: 0.014 μM
CREBBP, IC50: 0.018 μM
    
CBP/p300-IN-19
p300-HAT, IC50: 1.4 μM
CBP-HAT, IC50: 2.2 μM
PCAF, IC50: >100 μM
   
KCN1
p300